Document detail
ID

doi:10.1186/s12981-024-00632-5...

Author
Arora, Anish K. Vicente, Serge Engler, Kim Lessard, David Huerta, Edmundo Ishak, Joel Kronfli, Nadine Routy, Jean-Pierre Cox, Joseph Lemire, Benoit Klein, Marina Pokomandy, Alexandra Balso, Lina Sebastiani, Giada Vedel, Isabelle Quesnel-Vallée, Amélie Lebouché, Bertrand ASAP Migrant Advisory Committee
Langue
en
Editor

BioMed Central

Category

Medicine & Public Health

Year

2024

listing date

6/19/2024

Keywords
migrants hiv patient-reported outcomes care experience multidisciplinary satisfaction free region birth patient-reported experiences care hiv experience perceived measure treatment differed significantly scores
Metrics

Abstract

Background Scholars recommend providing migrants living with HIV (MLWH) with free treatment, rapidly, once linked to care to optimize their HIV-related experiences and health outcomes.

Quantitative evaluations of patient-reported measures for MLWH in such models are necessary to explore the viability of these recommendations.

Methods Within a 96-week prospective cohort study at a multidisciplinary HIV clinic, participants received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for free and rapidly following care linkage.

Eight patient-reported measures were administered at weeks 4, 24, and 48: (1) mMOS-SS to measure perceived social support; (2) IA-RSS to measure internalized stigma; (3) K6 to measure psychological distress; (4) PROMIS to measure self-efficacy with treatment taking; (5) G-MISS to measure perceived compliance with clinicians’ treatment plans; (6) HIVTSQ to measure treatment satisfaction; (7) CARE to measure perceived provider empathy; and (8) PRPCC to measure perceived clinician cultural competence.

Linear mixed modelling with bootstrapping was conducted to identify significant differences by sociodemographics and time.

Results Across weeks 4, 24, and 48, results suggest that MLWH enrolled in this study experienced moderate levels of social support; elevated levels of HIV-related stigma; moderate levels of distress; high self-efficacy with daily medication self-management; great compliance with clinicians’ treatment plans; high treatment satisfaction; high perceived empathy; and high perceived cultural competence.

Experience of social support (i.e., mMOS-SS scores) differed significantly by birth region.

Experience of HIV-related stigma (i.e., IA-RSS scores) differed significantly by birth region, age, and language.

Experience of distress (i.e., K6 scores) differed significantly by sexual orientation.

Experience of treatment satisfaction (i.e., HIVTSQ scores) differed significantly by birth region and age.

No significant differences were identified by time for any measure.

Conclusion Overall, participants expressed positive experiences around treatment and care, alongside comparably lower perceptions of social support, internalized stigma, and distress, potentially underscoring a need to embed targeted, well-funded, and accessible mental health support within HIV care models.

Arora, Anish K.,Vicente, Serge,Engler, Kim,Lessard, David,Huerta, Edmundo,Ishak, Joel,Kronfli, Nadine,Routy, Jean-Pierre,Cox, Joseph,Lemire, Benoit,Klein, Marina,Pokomandy, Alexandra,Balso, Lina,Sebastiani, Giada,Vedel, Isabelle,Quesnel-Vallée, Amélie,Lebouché, Bertrand,ASAP Migrant Advisory Committee, 2024, Patient-reported outcomes and experiences of migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite treatment dispensation: the ‘ASAP’ study, BioMed Central

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw